M
3.23
0.30 (10.24%)
| Previous Close | 2.93 |
| Open | 2.90 |
| Volume | 59,177 |
| Avg. Volume (3M) | 222,306 |
| Market Cap | 7,175,768 |
| Price / Sales | 1.75 |
| Price / Book | 1.71 |
| 52 Weeks Range | |
| Earnings Date | 1 Apr 2025 |
| Operating Margin (TTM) | -1,883.22% |
| Diluted EPS (TTM) | -44.40 |
| Quarterly Revenue Growth (YOY) | 4.60% |
| Total Debt/Equity (MRQ) | 228.39% |
| Current Ratio (MRQ) | 0.240 |
| Operating Cash Flow (TTM) | -19.31 M |
| Levered Free Cash Flow (TTM) | -12.58 M |
| Return on Assets (TTM) | -99.24% |
| Return on Equity (TTM) | -4,333.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Mainz Biomed N.V. | Bullish | Bullish |
AIStockmoo Score
-0.9
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.88 |
|
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company’s flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 4.98% |
| % Held by Institutions | 11.06% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Vontobel Holding Ltd. | 31 Dec 2024 | 0 |
| 52 Weeks Range | ||
| Median | 14.00 (333.44%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Maxim Group | 14 Feb 2025 | 14.00 (333.44%) | Buy | 6.04 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 Apr 2025 | Announcement | Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update |
| 27 Mar 2025 | Announcement | Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study |
| 03 Mar 2025 | Announcement | Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention |
| 20 Feb 2025 | Announcement | Mainz Biomed Expands into Switzerland with labor team w |
| 11 Feb 2025 | Announcement | Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month |
| 27 Jan 2025 | Announcement | Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements |
| 21 Jan 2025 | Announcement | Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |